RTTNews | Aug 24, 2020 08:27AM EDT

08:26 Monday, August 24, 2020 (RTTNews.com) - Catalent, Inc. (CTLT) announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford's COVID-19 vaccine, AZD1222, at Catalent's commercial gene therapy manufacturing facility located in Harmans, Maryland. Catalent's state-of-the-art Harmans/BWI commercial manufacturing facility is equipped with single-use technology, and houses over 200,000 square feet of late-stage clinical and commercial-stage gene therapy production.

Catalent agreed in June that the company's facility in Anagni, Italy, will provide large-scale vial filling and packaging of AZD1222.

Read the original article on RTTNews ( https://www.rttnews.com/3123396/catalent-s-maryland-facility-to-provide-manufacturing-support-for-astrazeneca-s-covid-19-vaccine.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved